New pill shows promise for Hard-to-Treat cancers
NCT ID NCT06558513
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new drug called XNW5004 in 120 people with advanced tumors or lymphoma that had come back or stopped responding to standard treatments. The goal was to check the drug's safety, find the right dose, and see if it helps shrink tumors. The drug is taken as a tablet twice a day.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
XNW5004 tablets (an EZH2 inhibitor)
What this could lead to
If successful, this could point toward a new treatment option for patients with advanced tumors or lymphoma who have not responded to standard therapies.
What could go wrong
This is an early-phase trial (Phase I/II) with a small number of participants, so the drug may not prove effective or safe in larger studies. Side effects are possible and being monitored.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hematology Hospital, Chinese Academy of Medical Sciences
Tianjin, China